<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30227836</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>11</Month>            <Day>05</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>05</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">1471-2407</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>18</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>18</Day>                    </PubDate>                </JournalIssue>                <Title>BMC cancer</Title>                <ISOAbbreviation>BMC Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>900</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-018-4811-x</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Triple Negative Breast Cancer (TNBC) is an aggressive form of breast cancer, that represents 10-20% of all breast carcinomas and characterized by the lack of a specific cell surface marker compared to other breast cancer subtypes. Due to the absence of molecular markers for TNBC his treatment options remains limited, without proven targeted therapies, which emphasize the need for discovering molecular markers that could be targeted for patient treatment, An important number of TNBC cases harbor aberrations in the phosphoinositide 3-kinase (PI3K) pathway, leading to constitutive activation of the downstream signaling pathway. Among mechanisms of PI3K enhancement, PIK3CA mutations are most frequently (~ 30%) observed, along with protein loss of PTEN and AKT activation by phosphorylation (pAkt). Therefore, we propose to analyze clinocopathologic and molecular characteristics of PI3K/AKT/PTEN pathway in Moroccan triple negative breast cancer patients.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a retrospective study of 39 patients diagnosed with triple negative breast cancer between early 2013 and 2016. In this study, we used the Ion Personal Genome Machine (PGM) and Ion Torrent Ampliseq Cancer panel to sequence hotspot regions from PIK3CA, AKT and PTEN genes to identify genetic mutations in 39 samples of TNBC subtype from Moroccan patients and to correlate the results with clinical-pathologic data.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">All patients were female with a median age of 46 years from (34-65). Most patients have had invasive ductal carcinoma (84.6%) and 69.2% of them were grade III SBR. Among the 39, 9 were right sided tumor patients and the remaining 30 were left-sided. Mutational analysis of PIK3CA gene was achieved in all TNBC patients. PIK3CA hotspot mutations were detected in 5/39 of TNBC (13%), in detail, among these 5 TNBC patients, one harbored mutation in exons 9 and four in exon 20.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The PI3KCA gene is highly activated and plays a crucial role in the pathogenesis of TNBC more, therefore, may be a potential therapeutic target to improve outcomes in patients.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Jouali</LastName>                    <ForeName>Farah</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Anoual Laboratory of Radio-Immuno Analysis, Angle Blvd Alexandrieet Blvd Anoual, 20360, Casablanca, Morocco. frh_0712@hotmail.com.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Laboratory of Pathophysiology and Molecular Genetics, Ben M'Sik Faculty of Science, 7955, Casablanca, Morocco. frh_0712@hotmail.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Marchoudi</LastName>                    <ForeName>Nabila</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Anoual Laboratory of Radio-Immuno Analysis, Angle Blvd Alexandrieet Blvd Anoual, 20360, Casablanca, Morocco.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Talbi</LastName>                    <ForeName>Salwa</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Center Hospital University Mohammed VI, 40080, Marrakech, Morocco.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bilal</LastName>                    <ForeName>Basma</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Center Hospital University Ibn Rochd, 20100, Casablanca, Morocco.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>El Khasmi</LastName>                    <ForeName>Mohamed</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Laboratory of Pathophysiology and Molecular Genetics, Ben M'Sik Faculty of Science, 7955, Casablanca, Morocco.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rhaissi</LastName>                    <ForeName>Houria</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Laboratory of Pathophysiology and Molecular Genetics, Ben M'Sik Faculty of Science, 7955, Casablanca, Morocco.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fekkak</LastName>                    <ForeName>Jamal</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Anoual Laboratory of Radio-Immuno Analysis, Angle Blvd Alexandrieet Blvd Anoual, 20360, Casablanca, Morocco.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>18</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>BMC Cancer</MedlineTA>            <NlmUniqueID>100967800</NlmUniqueID>            <ISSNLinking>1471-2407</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>EC 2.7.1.137</RegistryNumber>                <NameOfSubstance UI="D058534">Class I Phosphatidylinositol 3-Kinases</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.1.137</RegistryNumber>                <NameOfSubstance UI="C484760">PIK3CA protein, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.11.1</RegistryNumber>                <NameOfSubstance UI="D051058">Oncogene Protein v-akt</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 3.1.3.67</RegistryNumber>                <NameOfSubstance UI="D051059">PTEN Phosphohydrolase</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 3.1.3.67</RegistryNumber>                <NameOfSubstance UI="C494929">PTEN protein, human</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Mol Cell Biol. 2010 May;11(5):329-41</RefSource>                <PMID Version="1">20379207</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2012 Feb 9;366(6):520-9</RefSource>                <PMID Version="1">22149876</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 2008 Sep 18;27(42):5648-50</RefSource>                <PMID Version="1">18504432</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>NPJ Breast Cancer. 2017 Jul 3;3:24</RefSource>                <PMID Version="1">28685160</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2014 Oct 30;5(20):9952-65</RefSource>                <PMID Version="1">25296970</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2012 Mar 1;18(5):1341-51</RefSource>                <PMID Version="1">22261811</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Drug Discov. 2005 Dec;4(12):988-1004</RefSource>                <PMID Version="1">16341064</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2013 Jul 15;19(14):3738-44</RefSource>                <PMID Version="1">23748695</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Breast Cancer. 2015 Dec;15(6):473-481.e3</RefSource>                <PMID Version="1">26051240</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2005 Aug 10;23(23):5314-22</RefSource>                <PMID Version="1">15955899</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2007 Mar 8;446(7132):153-8</RefSource>                <PMID Version="1">17344846</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2015 Mar 20;17:43</RefSource>                <PMID Version="1">25887482</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2014 Oct;25(10):1973-9</RefSource>                <PMID Version="1">25009009</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2008 Aug 1;68(15):6084-91</RefSource>                <PMID Version="1">18676830</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Science. 2006 Oct 13;314(5797):268-74</RefSource>                <PMID Version="1">16959974</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2013 Jan 1;119(1):7-15</RefSource>                <PMID Version="1">22736407</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2008 Mar 10;26(8):1275-81</RefSource>                <PMID Version="1">18250347</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2006 Dec 20;24(36):5652-7</RefSource>                <PMID Version="1">17116942</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10350-4</RefSource>                <PMID Version="1">1332046</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2017 Feb;161(3):491-499</RefSource>                <PMID Version="1">27915434</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2007;9(5):R65</RefSource>                <PMID Version="1">17910759</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Science. 2004 Apr 23;304(5670):554</RefSource>                <PMID Version="1">15016963</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2007 Aug 15;110(4):876-84</RefSource>                <PMID Version="1">17620276</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Cancer Drug Targets. 2008 Feb;8(1):27-36</RefSource>                <PMID Version="1">18288941</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2015 Apr 1;21(7):1688-98</RefSource>                <PMID Version="1">25208879</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2015 Jun;151(3):541-53</RefSource>                <PMID Version="1">25981902</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18443-8</RefSource>                <PMID Version="1">16339315</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2012 Oct 4;490(7418):61-70</RefSource>                <PMID Version="1">23000897</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mod Pathol. 2016 May;29(5):476-88</RefSource>                <PMID Version="1">26939876</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2016 Aug 11;16:622</RefSource>                <PMID Version="1">27515171</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2012 Jun 20;486(7403):405-9</RefSource>                <PMID Version="1">22722202</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Appl Immunohistochem Mol Morphol. 2014 Jan;22(1):50-6</RefSource>                <PMID Version="1">24471188</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Science. 2002 May 31;296(5573):1655-7</RefSource>                <PMID Version="1">12040186</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2005 Dec 1;65(23):10992-1000</RefSource>                <PMID Version="1">16322248</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2015 Nov 05;10(11):e0141763</RefSource>                <PMID Version="1">26540293</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 2008 Sep 18;27(41):5497-510</RefSource>                <PMID Version="1">18794884</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA. 2006 Jun 7;295(21):2492-502</RefSource>                <PMID Version="1">16757721</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2007 Jul 26;448(7152):439-44</RefSource>                <PMID Version="1">17611497</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D058534" MajorTopicYN="N">Class I Phosphatidylinositol 3-Kinases</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009018" MajorTopicYN="N">Morocco</DescriptorName>                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D051058" MajorTopicYN="N">Oncogene Protein v-akt</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D051059" MajorTopicYN="N">PTEN Phosphohydrolase</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">AKT</Keyword>            <Keyword MajorTopicYN="N">PI3K pathway</Keyword>            <Keyword MajorTopicYN="N">PIK3CA</Keyword>            <Keyword MajorTopicYN="N">PTEN</Keyword>            <Keyword MajorTopicYN="N">Triple negative breast cancer</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>02</Month>                <Day>13</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>12</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>20</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>20</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30227836</ArticleId>            <ArticleId IdType="doi">10.1186/s12885-018-4811-x</ArticleId>            <ArticleId IdType="pii">10.1186/s12885-018-4811-x</ArticleId>            <ArticleId IdType="pmc">PMC6145190</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>